Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 2 countries.
Caroline B Costa-OrlandiDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-5752-6367
Níura M BilaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-4236-3366
Jean Lucas C BonattiDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.
Carolina O VasoDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-4629-680X
Mariana B SantosDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (U.N.E.S.P.), Sao Jose do Rio Preto 15054-000, SP, Brazil.
Carlos R PolaquiniDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (U.N.E.S.P.), Sao Jose do Rio Preto 15054-000, SP, Brazil.ORCID 0000-0001-5913-0246
Mariana M Santoni BiasioliDepartment of Biological Sciences, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.
Rondinelli D HerculanoDepartment of Bioprocesses and Biotechnology, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.
Luis O RegasiniDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (U.N.E.S.P.), Sao Jose do Rio Preto 15054-000, SP, Brazil.
Ana Marisa Fusco-AlmeidaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.
Maria José S Mendes-GianniniDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (U.N.E.S.P.), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-8059-0826
Universidade Estadual Paulista (Unesp) · BREduardo Mondlane University · MZ
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior finance code 001, 88887.500765/2020-00 (C.O.V.)Instituto de Bolsa de Estudos (I.B.E.) - Moçambique IBE150/2017 (N.M.B.)National Council for Scientific and Technological Development 142049/2019-0 (N.M.B), 105072/2018-4 (J.L.C.B.) and [134559/2018-5 (C.O.V.)]Pró-Reitoria de Pós-Graduação (P.R.O.P.G.) PDI-UNESP-00São Paulo Research Foundation 2017/18388-6 (C.B.C.-O.), 2019/22188-8 (N.M.B.), 2020/15586-4 (C.O.V.), and 2018/02785-9 (M.J.S.M.-G.)
6 · The paper itself
Abstract
The ability of dermatophytes to live in communities and resist antifungal drugs may explain treatment recurrence, especially in onychomycosis. Therefore, new molecules with reduced toxicity that target dermatophyte biofilms should be investigated. This study evaluated nonyl 3,4-dihydroxybenzoate (nonyl) susceptibility and mechanism of action on planktonic cells and biofilms of
Indexed as
anti-biofilm activityantifungal drugsbiofilmsdermatophytesmechanism of actionRT-PCR
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Membranolytic Activity Profile of Nonyl 3,4-Dihydroxybenzoate: A New Anti-Biofilm Compound for the Treatment of Dermatophytosis. · full record | OpenQuestion